Agilent

Q3 FISCAL YEAR 2026

FINANCIAL RESULTS OVERVIEW

Aug 26, 2026

Thank You for Your Attention

Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the impact relating to or arising from changes to tariffs, import/export or trade policies; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended April 30, 2026.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude charges primarily related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, and net (gain) loss on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.

Agilent 3Q26 Results

7.3% revenue growth(1)(2) beats high-end of guidance by 140 bps(2)

Operating margins also above guide by 190 bps (3)



- Topline strength led by high-single-digit instrument growth and nearly 30% growth in our specialty CDMO business
- Operating margin of 28.3%(2)(3), up 320 bps y/y driven by volume leverage and compounding Ignite efficiencies

Revenue
$1.88B
+8.1% reported
+7.3% core(1)(2)
+0.2% FX

Operating Margin
28.3% (2)(3)
+320 bps y/y
+190 bps q/q

EPS
$1.62 (2)(4)
+18% y/y

Capital Allocation
$519M operating cash flow
$78M to purchase 0.61M shares
$80M invested in capex
$72M in dividends

(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.
(3) Includes the net benefit from tariff refunds received in Q3 (110 bps).
(4) Includes the net benefit from tariff refunds received in Q3 (6 cents).

Q3 results once again demonstrate compounding value of the Ignite Operating System

LDG **23.5%** **Operating Margin**(2)(3)	**+10%** **Core Growth**(1)(2) **+11% Reported**	• Low double-digit LC growth against a mid-teens compare • Nearly 30% growth in Advanced Therapeutics Division
AMG **24.9%** **Operating Margin**(2)(3)	**+7%** **Core Growth**(1)(2) **+7% Reported**	• Strong demand supported by semiconductor momentum • >20% growth in PFAS testing
ACG **34.3%** **Operating Margin**(2)(3)	**+5%** **Core Growth**(1)(2) **+6% Reported**	• Strong consumables growth, improving China trends, and solid execution • Mid-single-digit Services growth in line with expectations

Definitions: LDG: Life Sciences and Diagnostics Markets Group, ACG: Agilent CrossLab Group, AMG: Applied Markets Group, LC: Liquid Chromatography, GC: Gas Chromatography, MS: Mass Spectrometry, CDx: Companion Diagnostics

(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.
(3) Includes net benefit from tariff refunds.

Agilent

GEOGRAPHY | PRODUCT TYPE

Core Revenue Growth by Geography

Americas and APAC (including China) deliver strong broad-based growth

- **Americas**
  40% of Agilent Revenue(2)
- **Europe**
  27% of Agilent Revenue(2)
- **Asia-Pacific (APAC)**
  33% of Agilent Revenue(2)



(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.
(2) % of Q3'26 Agilent revenue.

Agilent

GEOGRAPHY | PRODUCT TYPE

Q3 revenue mix

Recurring revenue mix remains healthy

Robust instrument growth, book-to-bill ≥1.0x for 10th consecutive quarter

% of total revenue

- Consumables, Services, Informatics: 66%
- Instruments: 34%

Agilent

Q3 REVENUE

Exceptional execution supported by…

…continued improvement in our largest end markets, replacement-cycle, innovation-led share gains and compounding Ignite momentum

		Q3 Core Growth(1) Results	Share of Agilent Revenue(2)
Pharma	Biotech momentum, robust GLP-1 contribution and nearly 30% growth in Advanced Therapeutics Division	+12%	38%
Diagnostics & Clinical	Strength driven by Companion Diagnostics demand, Genomics growth; Pathology orders up double-digits	+6%	15%
Academia & Government	Muted but stabilizing research funding environment with low single digits growth ex-China	-3%	7%
Chemicals & Advanced Materials	Growth led by Advanced Materials on robust semiconductor demand	+7%	23%
Environmental & Forensics	Continued strength in Environmental driven by PFAS momentum	+5%	9%
Food	Exceeded expectations against a tough compare with strong performance in China	+0%	8%

(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.
(2) % of Q3'26 Agilent revenue.

Agilent

FY26 Guidance[(1)]

Increasing core revenue growth[(2)], margin expansion[(3)] and EPS outlook[(4)]

Updated outlook reflects increased confidence in business performance

Net Revenue ($)	$7.49B ⟷ $7.51B	+$60M at the midpoint vs. prior guide
Core Revenue Growth[(2)]	+5.8% ⟷ +6.0% (+1.6% FX)	+65 bps at the midpoint vs. prior guide
Operating Margins [(3)]	>130 bps YoY	>45 bps vs. prior guide
EPS [(4)]	$6.18 ⟷ $6.21	+$0.15 at midpoint vs. prior guide

$31M FY26	Net Interest + Other Inc/(Exp)
$1.6-1.7B FY26	Operating Cash Flow
$290M FY26	Dividends
14.5% FY26	Tax Rate
$450M FY26	CapEx
283M FY26	Share Count

Anti-dilutive share repurchases at a minimum [(5)]

(1) Based on forecasted currency exchange rates. Presented on a non-GAAP basis.
(2) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX..
(3) Includes net benefit from tariff refunds received in Q3’26 (30 bps).
(4) Includes the net benefit from tariff refunds received in Q3 (6 cents).
(5) The 2024 repurchase program became effective on August 1, 2024 and commenced upon completion of our 2023 repurchase program in September 2025.

Agilent

4Q26 Guidance[1] [3]

Expect YTD momentum to continue

Reflects healthy demand trends across largest end markets

	Low		High	
Net Revenue ($B)	$1.98B	↔	$2.00B	
Core Revenue Growth[2]	+5.2%	↔	+6.2%	-0.1% FX
EPS [3]	$1.71	↔	$1.74	

$4M Q4	Net Interest + Other Inc/(Exp)	283M Q4	Share Count

(1) Based on forecasted currency exchange rates. Presented on a non-GAAP basis.
(2) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.
(3) Does not include any future benefit from potential tariff refunds.

Agilent

Agilent

Trusted Answers



Get in touch with us

investor_relations@agilent.com

www.investor.agilent.com